

## Special Issue

# Development of Attenuated Vaccine

### Message from the Guest Editor

It is a fact from many research results so far that vaccine platforms such as inactivated vaccines and component vaccines cannot induce sufficient protective immunity. Vaccine development has evolved in pathogens, such as: parasites, viruses and bacteria. Here we want to propose the theme aims to contribute to the development of attenuated vaccines by collecting attenuating strategies for a wide range of pathogens. As we are now aware that, the most powerful tools for controlling pathogens is vaccine. Attenuated vaccines are the most powerful tools for inducing protective immunity. Regarding as the development of current genetic engineering with safe and easy way, the development of artificially attenuated vaccines is being realized. In this topic, we call about (1) pathogen-associated molecules targeted by protective immunity, (2) the virulence factor, (3) immune response induced by a genetically manipulated pathogen, and (4) a new vaccine platform. We look forward to call for paper on the subject.

### Guest Editor

Dr. Kazutomo Suzue

Department of Infectious Diseases and Host Defense, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan

### Deadline for manuscript submissions

closed (30 June 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/92811](https://mdpi.com/si/92811)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).